NCT05067179 Analysis of Human ALS Tissues and Registry of ALS Patients
| NCT ID | NCT05067179 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Illinois at Chicago |
| Condition | Amyotrophic Lateral Sclerosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2020-09-01 |
| Primary Completion | 2030-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2020-09-01 with a primary completion date of 2030-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig's Disease, is a progressive, terminal condition of muscle weakness that is associated with degeneration of neurons in the spinal cord and brain. This devastating disorder afflicts people in the prime of their lives. At the present time, there are no cures for this disorder, and current treatments are marginal at best. Despite years of intensive research, a fundamental understanding of this disease is still lacking. There is a need to identify both reliable markers of disease progression and effective treatments. The goal of this research is to bring a greater understanding of ALS patients closer to the research studies that can lead to new hypotheses and approaches.
Eligibility Criteria
Inclusion Criteria: * Patients over the age of 18 * Established diagnosis of ALS * Able and willing to give written informed consent and must authorize release and use of protected health information Exclusion Criteria: * Patients below the age of 18 * No diagnosis of ALS
Contact & Investigator
Jeffrey Loeb, MD
PRINCIPAL INVESTIGATOR
University of Illinois at Chicago
Frequently Asked Questions
Who can join the NCT05067179 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Amyotrophic Lateral Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05067179 currently recruiting?
Yes, NCT05067179 is actively recruiting participants. Contact the research team at afasawe@ilstu.edu for enrollment information.
Where is the NCT05067179 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT05067179 clinical trial?
NCT05067179 is sponsored by University of Illinois at Chicago. The principal investigator is Jeffrey Loeb, MD at University of Illinois at Chicago. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.